GSK PLC announced that the U.S. Food and Drug Administration (FDA) has accepted the biologics license application (BLA) for Blenrep (belantamab mafodotin-blmf) in combination with bortezomib and dexamethasone (BorDex) and pomalidomide and dexamethasone (PomDex) for the treatment of relapsed or refractory multiple myeloma. This application seeks approval for patients who have received at least one prior line of therapy. The FDA is expected to make a decision by July 23, 2024.
The application is supported by data from the DREAMM-7 and DREAMM-8 phase III trials. Both trials met their primary endpoints, demonstrating statistically significant and clinically meaningful improvements in progression-free survival (PFS). These findings underscore the potential of Blenrep combinations to address the unmet needs of patients with relapsed or refractory multiple myeloma.
Clinical Trial Data
The DREAMM-7 and DREAMM-8 trials are pivotal studies evaluating the efficacy and safety of Blenrep-based combinations. Hesham Abdullah, Global Head Oncology, R&D at GSK, noted that the U.S. application is based on results from these trials, which showed statistically significant and clinically meaningful improvements in progression-free survival.
Multiple Myeloma Landscape
Multiple myeloma is the third most common type of blood cancer, with over 180,000 new cases diagnosed globally each year. In 2024, more than 35,000 cases are expected to be diagnosed in the United States alone. While multiple myeloma is treatable, the disease often becomes resistant to available treatments, highlighting the need for new therapeutic options.
This regulatory filing marks the sixth major acceptance for Blenrep combinations in the treatment of relapsed and refractory multiple myeloma, following recent approvals in the UK and Europe. The acceptance of the BLA by the FDA represents a significant step forward in providing new treatment options for patients with this challenging disease.
